Mayzent

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, State University of New York at Buffalo

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)Secondary-progressive Multiple Sclerosis

Phase 2

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

TerminatedNCT04925557

State University of New York at BuffaloSecondary-progressive Multiple Sclerosis

Start: 2021-11-13End: 2023-08-05Updated: 2025-05-13

Unknown Phase

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

CompletedNCT04593927

Novartis PharmaceuticalsSecondary Progressive Multiple Sclerosis (SPMS)

Start: 2020-10-28End: 2023-08-30Updated: 2024-02-12